GlassScriptPhysician profile
Urvi Patel
NPI 1265656185
$6,206.19
in general payments reported to CMS, 2019-2025
34 companies · $2,358 in 2025
The $2,358 reported for 2025 was more than what 95% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $1,452 · 2024: $2,397 · 2025: $2,358.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,195 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,194.90 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $975.81 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $819.03 | 2023-2025 | Ozempic, Rybelsus, Wegovy |
| Corcept Therapeutics | $567.62 | 2023-2025 | Korlym |
| Cequr Corporation | $439.14 | 2023-2025 | Cequr Simplicity |
| Sanofi-Aventis U.S. LLC | $430.71 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $369.17 | 2023-2025 | Recorlev, Gvoke Hypopen |
| Radius Health, INC. | $294.77 | 2023-2025 | Tymlos |
| Insulet Corporation | $259.03 | 2023-2025 | Omnipod |
| Amneal Pharmaceuticals LLC | $217.94 | 2023-2025 | Unithroid |
| Tandem Diabetes Care, INC. | $174.05 | 2023-2024 | T:Slim X2 Insulin Pump With Control-Iq |
| Amgen INC. | $146.19 | 2023-2025 | Evenity, Prolia, Prolia |
| Abbvie INC. | $137.61 | 2024-2025 | |
| Recordati_rare_diseases_inc. | $131.00 | 2023-2025 | Isturisa, Signifor Lar |
| Amphastar Pharmaceuticals, INC. | $121.99 | 2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.12 | 2025 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $100.33 | 2023-2025 | Strensiq |
| Antares Pharma, INC. | $99.27 | 2024-2025 | Xyosted |
| Madrigal Pharmaceuticals | $90.07 | 2025 | Rezdiffra |
| Medtronic, INC. | $88.76 | 2024 | Minimed 780g |
| Boehringer Ingelheim Pharmaceuticals, INC. | $86.27 | 2023-2025 | Jardiance |
| Tolmar, INC. | $81.44 | 2023-2025 | Jatenzo |
| Arcutis Biotherapeutics, INC. | $63.60 | 2025 | Zoryve |
| Abbott Laboratories | $56.72 | 2023-2024 | Freestyle Libre 3, Freestyle Libre 2 |
| Acella Pharmaceuticals, LLC | $49.74 | 2024-2025 | NP Thyroid 60 |
| Dexcom, INC. | $48.13 | 2024-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $46.57 | 2023-2025 | Veozah |
| Halozyme INC | $42.25 | 2023 | |
| Boston Scientific Corporation | $28.04 | 2025 | Wavewriter Alpha Prime 16 |
| Embecta Corp. | $27.44 | 2023 | Bd Nano 2nd Gen Pen Needle |
| Beta Bionics, INC. | $26.83 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Daiichi Sankyo INC. | $23.72 | 2024 | Enhertu |
| Neurocrine Biosciences, INC. | $20.58 | 2024 | |
| Astrazeneca Pharmaceuticals LP | $19.80 | 2025 | |
| Amryt Pharma Holdings LTD | $15.45 | 2023 | Mycapssa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Urvi Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.